Received Jun 15, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | PK539 | — |
Pharmacist described the rash ;It was not a rash at the injection site, it was a rash like shingles.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of vesicular rash in a 70-year-old female patient who received Herpes zoster (Shingrix) solution for injection (batch number PK539 with expiry date 03-MAR-2028) for prophylaxis. Previously administered products included Zostavax vaccine (Received on 2017). On 27-MAY-2026, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced vesicular rash (Verbatim: Pharmacist described the rash ;It was not a rash at the injection site, it was a rash like shingles.). The outcome of the vesicular rash was not reported. It was unknown if the reporter considered the vesicular rash to be related to Shingrix. Additional Information: GSK Receipt Date: 11-JUN-2026 The pharmacist called on June 11, 2026, to report that a patient had presented with a rash outbreak after receiving the first dose of the Shingrix vaccine. The pharmacist stated that the rash had not appeared at the injection site. The pharmacist described the rash as resembling shingles rather than a typical post injection reaction. The pharmacist explained, "It wasn't a rash at the injection site; it was a rash like shingles. It was just a real minor case of it. She felt like she had an outbreak of shingles. The pharmacist reported that the patient had previously received the Zostavax vaccine in 2017. The batch number was not provided upon follow up with the reporter